Intrexon | XON - Equity Capital And Reserves


Intrexon reported $43.17M in Equity Capital and Reserves for its fiscal quarter ending in June of 2024.





Equity Capital And Reserves Change Date
Agenus USD -199.08M 22.15M Jun/2026
Alaunos Therapeutics USD 652K 636K Jun/2026
Amgen USD 14.35B 2.66B Sep/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 465.53M 148.45M Jun/2026
AstraZeneca USD 51.73B 1.43B Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Gilead Sciences USD 13.04B 1.3B Sep/2026
GlaxoSmithKline GBP 18.75B 1.11B Sep/2026
Heron Therapeutics USD 6.91M 2.23M Jun/2026
Incyte USD 5.64B 701.49M Sep/2026
Intrexon USD 43.17M 75.33M Jun/2024
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
Ligand Pharmaceuticals USD 961.76M 5.75M Sep/2026
MacroGenics USD 42.87M 21.68M Jun/2026
MannKind USD -37.27M 29.93M Sep/2026
Merck USD 44.89B 2.96B Sep/2026
Novartis USD 37.23B 4.72B Sep/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 32.69B 1.11B Jun/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Thermo Fisher Scientific USD 54.76B 2.08B Sep/2026
Veracyte USD 1.43B 44.86M Sep/2026
Xencor USD 560.43M 57.21M Sep/2026